Akebia Therapeutics, Inc. (AKBA) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Akebia Therapeutics (AKBA) by buying shares or fractional shares at any major US broker, through a small-cap biotech or healthcare ETF that holds it, or as one holding in a thematic basket. Akebia is a commercial-stage biopharmaceutical company focused on kidney disease. Its core value driver is Vafseo (vadadustat), an oral HIF-PH inhibitor for anemia due to chronic kidney disease in dialysis patients, which launched in the US in January 2025. It also sells Auryxia (ferric citrate) and is building a rare kidney disease pipeline. The central thing to understand is that this is a small, single-therapy-area biopharma whose story hinges on how fast Vafseo scales against an entrenched injectable standard of care.
AKBA stock price
As of 2026-07-14, Akebia Therapeutics, Inc. (AKBA) last closed at $1.40, down 64.6% over the past year. Over the past 52 weeks it has traded between $0.8730 and $4.01.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Akebia Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Akebia Therapeutics, Inc. (AKBA) do?
Akebia Therapeutics is a commercial-stage biopharmaceutical company built around treating kidney disease. Its flagship product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in the US to treat anemia caused by chronic kidney disease (CKD) in adults on dialysis. Vafseo launched in the US in January 2025 and is the company's primary growth engine. Akebia's second marketed product is Auryxia (ferric citrate), used to control serum phosphorus in dialysis patients and to treat iron deficiency anemia in non-dialysis CKD patients.
The investment picture in 2026 is a tale of two products. Vafseo is ramping: Q1 2026 net product revenue reached about $15.8 million, the number of patients treated rose roughly 60% versus the prior quarter, and access expanded to hundreds of thousands of dialysis patients as more dialysis organizations and prescribers adopted it. Auryxia, by contrast, is declining as generic competition expands in 2026, with management guiding Auryxia revenue lower year over year. Total net product revenue was about $52 million in Q1 2026.
Beyond the two commercial products, Akebia is establishing a rare kidney disease pipeline, including praliciguat in focal segmental glomerulosclerosis (FSGS) and AKB-097, plus longer-term studies such as VOICE intended to broaden Vafseo's clinical profile. As a small biopharma concentrated in one therapy area, Akebia's results and share price are highly sensitive to the pace of the Vafseo launch, reimbursement dynamics in the dialysis channel, and cash needs to fund commercialization and trials.
What's driving Akebia Therapeutics, Inc. (AKBA)?
1. Vafseo launch trajectory
Vafseo is the core of the story: an oral alternative in a dialysis anemia market long dominated by injectable erythropoiesis-stimulating agents. Early launch metrics have been encouraging, with patient starts, prescriber counts, and net revenue rising quarter over quarter and broad payer coverage across dialysis patients. How steeply this adoption curve continues is the single biggest swing factor for the company's revenue and path toward profitability.
2. Dialysis channel and reimbursement
Anemia treatment for dialysis patients runs through large dialysis organizations and Medicare reimbursement structures. Favorable reimbursement pathways that let dialysis providers be paid for using Vafseo are central to uptake, since providers weigh cost and clinical fit closely. Wins or setbacks in coverage, bundling, and dialysis-organization adoption move the Vafseo forecast more than most company-specific factors.
3. Rare kidney disease pipeline
Akebia is extending beyond its two marketed drugs into rare kidney diseases, including a praliciguat Phase 2 study in FSGS and an AKB-097 basket trial planned to begin in the second half of 2026, with initial data expected in 2027. A longer-horizon VOICE study aims to strengthen Vafseo's evidence base. These programs offer optional upside but carry the usual clinical, regulatory, and timing risk of early-stage trials.
4. Managing the Auryxia decline
Auryxia has been a meaningful revenue contributor, but generic competition is expanding in 2026 and management expects Auryxia revenue to fall year over year. The company's near-term financial health depends on Vafseo growth outrunning the Auryxia erosion, alongside disciplined operating expense and cash management. The mix shift from a declining legacy product to a ramping new one defines the transition Akebia is navigating.
What are the risks to Akebia Therapeutics, Inc. (AKBA)?
The dominant risk is concentration: Akebia is a small-cap biopharma whose fortunes rest heavily on a single product launch, so any slowdown in Vafseo uptake, reimbursement, or competition from injectable ESAs and rival HIF-PH inhibitors could quickly reset the thesis. Auryxia revenue is declining as generics expand, pressuring total sales during the Vafseo ramp. As a company at this scale, Akebia may need to fund commercialization and clinical trials from cash, debt, or equity, and any capital raise could dilute shareholders or add leverage. Pipeline programs in FSGS and other rare kidney diseases face clinical, regulatory, and timing uncertainty, with key readouts still years away. The stock can be volatile on launch metrics, quarterly revenue, trial news, and financing announcements.
How is Akebia Therapeutics, Inc. (AKBA) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Akebia Therapeutics, Inc.'s investor relations page or your broker.
- Revenue (TTM): roughly $230 to $240 million (trailing twelve months as of late 2025)
- Q1 2026 total net product revenue: about $52 million (Vafseo ~$15.8M, Auryxia ~$36.2M)
- Vafseo growth: patients treated up roughly 60% versus the prior quarter; net revenue growing sequentially
- Auryxia trend: declining, with generic competition expanding in 2026 and revenue guided lower year over year
- Profitability: a commercial-stage biopharma still investing heavily in the launch and pipeline; watch for the path toward sustained profitability
- Market cap: small-cap; verify the live figure, as it swings sharply with launch and trial news
Figures are approximate and tied to the asOf date; verify live numbers before acting. For a small commercial-stage biopharma, traditional earnings multiples are of limited use because the company is in an investment phase and profitability depends on how fast Vafseo scales relative to spending. Investors typically watch product revenue trends, patient and prescriber counts, cash runway, and pipeline readouts more than a single P/E figure.
Who competes with Akebia Therapeutics, Inc. (AKBA)?
Anemia treatments in dialysis
Vafseo competes primarily against injectable erythropoiesis-stimulating agents (ESAs) that have long been the standard of care for anemia in dialysis patients, such as those from Amgen and related biosimilars, as well as other oral HIF-PH inhibitors developed by large pharma. The competitive question is whether an oral option can displace entrenched injectables in the dialysis channel.
Phosphate binders and iron therapies
Auryxia (ferric citrate) competes as a phosphate binder and iron-deficiency-anemia treatment against other prescription binders, over-the-counter and prescription oral iron formulations, and intravenous iron products. Expanding generic ferric citrate competition in 2026 adds direct pricing and volume pressure to this part of Akebia's portfolio.
Rare kidney disease developers
In its emerging rare kidney disease pipeline, Akebia lines up against specialty nephrology biopharma companies such as Travere Therapeutics, Calliditas, and Alnylam that develop treatments for conditions like FSGS and other glomerular diseases. These are pipeline-stage rivals rather than current commercial competitors, and outcomes depend on clinical trial results.
How to invest in Akebia Therapeutics, Inc. (AKBA)
There are three common ways to get AKBA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so AKBA sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where AKBA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Akebia Therapeutics, Inc. (AKBA)
Akebia is a small-cap kidney-disease biopharma turning on the Vafseo launch: a real, growing oral product in a large dialysis market, offset by Auryxia decline from generics, a narrow product base, and the execution and financing risk typical of a company at this scale.
Build a basket around AKBA with Walnut
Use Akebia Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is AKBA a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a growing Vafseo launch in a large dialysis anemia market, broad payer access, and an emerging rare kidney disease pipeline. The bear case is heavy dependence on one product, declining Auryxia revenue from generics, potential financing needs at a small-cap scale, and the general volatility of commercial-stage biopharma. Weigh both against your portfolio and consider your own research.
What does Akebia Therapeutics actually do?
+
Akebia is a biopharmaceutical company focused on kidney disease. It markets Vafseo (vadadustat), an oral HIF-PH inhibitor for anemia due to chronic kidney disease in dialysis patients, and Auryxia (ferric citrate) for phosphorus control and iron deficiency anemia. It is also developing treatments for rare kidney diseases. Its results track how well these products sell and how its pipeline progresses.
What is Vafseo and why does it matter?
+
Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in the US to treat anemia caused by chronic kidney disease in adults on dialysis. It matters because it is Akebia's primary growth driver and offers an oral alternative in a market historically served by injectable erythropoiesis-stimulating agents. Its US launch began in January 2025.
Why is AKBA stock volatile?
+
Akebia is a small-cap, commercial-stage biopharma concentrated in one therapy area, so its share price reacts sharply to quarterly product revenue, Vafseo launch metrics, reimbursement news, clinical trial readouts, and any financing announcements. With much of the value tied to a single launch, small changes in the outlook can move the stock significantly in either direction.
How is the Vafseo launch going?
+
Early metrics have been encouraging. In Q1 2026 Vafseo net product revenue reached about $15.8 million and the number of patients treated rose roughly 60% versus the prior quarter, with new patient starts at their highest since the initial launch quarter and broad access across dialysis patients. Investors watch these launch metrics closely each quarter, so check the latest reported figures.
What is happening with Auryxia?
+
Auryxia (ferric citrate) remains a marketed product for phosphorus control and iron deficiency anemia, but generic competition is expanding in 2026 and management expects Auryxia revenue to decline year over year. The company's near-term revenue trajectory depends on Vafseo growth offsetting this Auryxia erosion during the transition.
Does Akebia pay a dividend?
+
Akebia is a commercial-stage biopharmaceutical company reinvesting in its product launch and pipeline, so it does not fit the profile of a dividend payer. Investors in a company at this stage are generally focused on revenue growth and clinical progress rather than income. Always check the latest company disclosures before assuming any dividend policy.
What are the main risks of investing in AKBA?
+
The central risk is concentration on the Vafseo launch, so any slowdown in uptake, reimbursement setbacks, or competition from injectable ESAs and other HIF-PH inhibitors could reset the thesis. Declining Auryxia revenue, potential capital raises that dilute shareholders, and pipeline trial uncertainty add to the risk. As a small-cap biopharma, the stock can move sharply on launch data, earnings, and trial news.
How can I get exposure to Akebia through an ETF?
+
AKBA can appear in small-cap, biotechnology, or broad healthcare ETFs, though as a small company its weighting in any diversified fund is typically minor. ETF exposure spreads single-stock risk across many holdings but dilutes how much an Akebia move affects you. Always review a fund's holdings and weights before assuming meaningful exposure to AKBA specifically.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Akebia Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.